Although our study identified possible pathological roles for IGF1, ESR1, and CXCL12 in breast cancer and a potential synergistic effect of formononetin with immune checkpoint inhibitors in breast cancer immunotherapy, the limitation of this study is that it is only a data analysis-based prediction. Here, IGF1 is linked to breast carcinoma.